Gilead Sciences's most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $70.00 short put and a strike $65.00 long put offers a potential 7.53% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $70.00 by expiration. The full premium credit of $0.35 would be kept by the premium seller. The risk of $4.65 would be incurred if the stock dropped below the $65.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 42.98 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
How Do Drugs Compete Against Each Other?
Fri, 21 Sep 2018 04:00:00 +0000
Investors can keep an eye on these four factors to tell which drugs will out-compete the rest.
Shire’s Quarterly Revenue Trend
Thu, 20 Sep 2018 20:55:02 +0000
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.
Study shows PrEP effective at stopping HIV infections
Thu, 20 Sep 2018 20:23:03 +0000
Gilead's drug Truvada, used in conjunction with pre-exposure prophylaxis, can reduce HIV infection rates, a study has found. That's important news for regions of the U.S. like the South, where infection rates are high and continuing to rise.
Curing AIDS: After antiretrovirals brought the disease under control, a more ambitious goal is now in sight
Thu, 20 Sep 2018 19:53:24 +0000
Researchers at Gilead, UCSF and elsewhere are hopeful that a cure could be available in five to 20 years. But a difficult issue must be resolved first: To test any “cure,” HIV patients at some point will have to be taken off today’s life-saving antiretroviral therapies.
Ultragenyx's Shares Surge More Than 80% in the Year So Far
Thu, 20 Sep 2018 19:49:07 +0000
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Also on Market Tamer…
Follow Us on Facebook